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Background: The aim of this study was to compare the ability of four commercially available media for screening
extended-spectrum beta-lactamase (ESBL) to detect and identify ESBL-producing Salmonella and Shigella in fecal
samples.
A total of 71 Salmonella- and 21 Shigella-isolates producing ESBLA and/or AmpC, were received at Norwegian
Institute of Public Health between 2005 and 2012. The 92 isolates were mixed with fecal specimens and tested on
four ESBL screening media; ChromID ESBL (BioMèrieux), Brilliance ESBL (Oxoid), BLSE agar (AES Chemunex) and
CHROMagar ESBL (CHROMagar). The BLSE agar is a biplate consisting of two different agars. Brilliance and
CHROMagar are supposed to suppress growth of AmpC-producing bacteria while ChromID and BLSE agar are
intended to detect both ESBLA and AmpC.
Results: The total sensitivity (ESBLA + AmpC) with 95% confidence intervals after 24 hours of incubation were as
follows: ChromID: 95% (90.4-99.6), Brilliance: 93% (87.6-98.4), BLSE agar (Drigalski): 99% (96.9-100), BLSE agar
(MacConkey): 99% (96.9-100) and CHROMagar: 85% (77.5-92.5). The BLSE agar identified Salmonella and Shigella
isolates as lactose-negative. The other agars based on chromogenic technology displayed Salmonella and Shigella
flexneri isolates with colorless colonies (as expected). Shigella sonnei produced pink colonies, similar to the
morphology described for E. coli.
Conclusion: All four agar media were reliable in screening fecal samples for ESBLA-producing Salmonella and
Shigella. However, only ChromID and BLSE agar gave reliable detection of AmpC-producing isolates. Identification
of different bacterial species based on colony colour alone was not accurate for any of the four agars.
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Antimicrobial resistance is an increasing challenge of
global proportions [1]. Special emphasis has been put on
Gram negative bacteria producing enzymes conferring re-
sistance against beta lactam antibiotics, such as third and
fourth generation cephalosporins, monobactams and car-
bapenems, commonly known as extended spectrum beta-
lactamases (ESBLs) [2-4]. ESBLs are associated with higher
morbidity and mortality, rising health care costs [5], poten-
tial for foodborne transmission [6,7] and asymptomatic
carriage [8]. ESBL-producing bacteria most often reside in* Correspondence: astrid.louise.wester@fhi.no
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unless otherwise stated.the intestine of humans and animals, and may thus be dif-
ficult to control and eradicate [9,10]. Plasmid mediated
ESBL genes can be transferred between different strains of
bacteria and between different bacterial species and genera
within the Enterobacteriaceae family [11]. Co-resistance
to other groups of antibiotics is frequently observed in
ESBL-producing organisms, which makes the choice of
effective treatment even more limited [12]. In the Nordic
countries, recent studies state that the main risk factor for
acquiring ESBL-producing bacteria is travel abroad
[13-15]. Asymptomatic infections with Salmonella and
Shigella do occur [16,17]. When screening for fecal car-
riage of ESBL, the methods must ensure reliable detection
also of these bacterial species. This is especially important
after travel to countries with high prevalence of bothLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lence of these particular pathogens.
The Nordic Committee on Antimicrobial Susceptibility
Testing (NordicAST) categorises ESBLs into three broad
categories, ESBLA, ESBLM and ESBLCARBA according
to the classification suggested by Giske et al. [18]. The
ESBLA- group consists of the classical ESBLs, which
are inhibited by clavulanic acid. The group of miscellan-
eous ESBLs (ESBLM) contains plasmid-mediated AmpC
and several of the OXA-enzymes. The last category of
ESBLs, the ESBLCARBA, consists of enzymes that have the
ability to inactivate carbapenems.
In this study, Salmonella- and Shigella-isolates classified
as ESBLA and/or ESBLM were included according to
genotype. All isolates belonging to the ESBLM-group
were AmpC-genotypes. Several Enterobacteriaceae have
chromosomally encoded AmpC-genes but normally the
gene expression of these genes is down-regulated [18].
Within genus Salmonella the AmpC-gene is not present
in the chromosomal genome and AmpC-producing Sal-
monella are thus a product of plasmid mediated AmpC
(pAmpC) [19].
To ensure appropriate treatment and to minimize the
risk of spread to other patients it is important to detect
ESBL-producing strains as early as possible [20]. The fecal
carriage rate of ESBL-producing bacteria in healthy popu-
lations is increasing, and effective screening-methods for
surveillance purposes become increasingly important [8].
Various methods for ESBL-detection have been described,
both direct screening on clinical specimens and screening
of bacterial isolates [21]. In Norway, clinically relevant
strains are routinely tested for the presence of ESBLs, but
presently there are guidelines neither on indications nor
microbiological strategies for fecal screening. A recent re-
port from the Norwegian Institute of Public Health
(NIPH) suggests that patients transferred from hospitals
abroad into intensive care units or dialysis units should be
screened for fecal carriage of ESBL [22]. However, hospital
laboratories may apply different approaches for ESBL
screening [23]. In recent years, a variety of ESBL screening
media have become commercially available, some which
uses chromogenic technology for the direct ESBL-
detection in fecal samples. These ESBL screening media
are designed to detect and identify ESBL-producing
bacteria among the whole Enterobacteriaceae family.
The identification of different bacterial species on ESBL
screening media is generally based on the enzymatic
degradation of different carbohydrates and peptides.
Salmonella, and some species of Shigella, have different
sugar degradation profiles than the most predominant
cultivatable species within normal fecal flora. So far,
most published studies have focused on ESBL-detection
in Escherichia coli and Klebsiella spp. No studies, except one
of the manufacturers’, have described how ESBL-producingSalmonella or Shigella will appear on these four culture
media. The aim of this study was therefore to compare
commercially available ESBL-screening media to determine
their ability to detect and identify of ESBL-producing
Salmonella and Shigella in fecal specimens.
Methods
The study was carried out at the Norwegian Institute of
Public Health (NIPH), Department of Food-borne Infec-
tions. This department is the national reference laboratory
for food-borne infections and is also responsible for the
reporting of antimicrobial resistance in enteropathogenic
bacteria at a national level. In 2005, the laboratory initiated
screening for ESBL in these bacteria. Since then, nearly 100
ESBL-producing strains of Salmonella spp. and Shigella
spp. have been identified from patients in Norway.
A total of 92 unique isolates Salmonella and Shigella
spp. carrying ESBLA or AmpC genotypes collected between
2005 and 2012 were included based on inhibition zone
diameter of ≤ 21 mm against cefpodoxime (Cefpodoxime
10 mcg disc, BBL Sensi-Disc, BD), on Mueller Hinton agar.
Genotyping of ESBL-producing strains
Prior to the inoculation of the bacteria onto the ESBL agar
media, the isolates were characterized by ESBL genotyping.
DNA was released from bacterial suspensions of the iso-
lates by heat treatment (95°C, 5 min) and first tested in
three ESBLA PCR assays [24]. As a part of this study, and
without changing the primer sequences these ESBLA assays
were converted into real-time PCR format to enable DNA
melt analysis. The real-time PCR adaption of the protocol
was achieved through use of the double-strand-DNA-spe-
cific fluorescent reporter dye SYTO®9 (Invitrogen), the am-
monium sulfate/Tris-based PCR buffer IV (ABgene®) and
Platinum Taq DNA polymerase (Invitrogen) [25,26]. The
amplification and the subsequent DNA melting of the
amplification products were done in a StepOnePlus™ Real-
Time PCR instrument (Life Technologies™). The three
ESBLA real-time PCR assays indicated presence of blaTEM,
blaSHV, and blaCTX-M in the samples. In addition, the bac-
terial DNA was also tested in two ESBLM triplex PCR
assays by use of the published primers and primer com-
binations as blaCIT/blaMOX/blaFOX and blaDHA/blaACC/
blaEBC [27]. Without change of the AmpC primer sequences,
the reaction conditions of the two triplex assays were
modified, as for the above ESBLA assays, to SYTO®9-based
real-time PCR. The DNA melt analysis discriminated the
various products of the two AmpC triplex PCR assays. All
of the ESBL-positive PCR products were subjected to bidir-
ectional DNA sequencing to confirm the real-time results.
Finally the ESBLA and AmpC isolates were sub-typed by
comparison to a BioEdit database made from sequences de-
posited in GenBank (http://blast.ncbi.nlm.nih.gov/Blast.cgi)
according to the beta-lactamase classification in the Lahey
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92 isolates originally included in the study based on the
cefpodoxime screening test (disc diffusion test) were
found to be ESBL-negative by PCR. One of the PCR-
positive isolates did not grow on subculture. These five
strains were excluded from the study, resulting in a total
of 87 eligible isolates. Of the 87 isolates included in the
study there were 17 isolates of Shigella sonnei, two isolates
of Shigella flexneri, 18 isolates of Salmonella Typhimurium,
12 isolates of S. Stanley, seven isolates of S. Concord,
five isolates of S. Enteritidis and 16 isolates of other
non-Typhoid Salmonella.
Fecal samples
To mimic fecal samples, we followed the same proced-
ure as has been applied in the Norwegian external qual-
ity control program, organized by the NIPH. A fecal
suspension from a healthy person was prepared, after
controlling for the absence of Salmonella and Shigella.
The donor fecal material was diluted (approximately 1:5)
with isotonic NaCl solution (0.9%). A part of the sus-
pension was heated (80°C, 1 hour) to prevent bacterial
overgrowth from intestinal flora on the ESBL screening
agars. For each of the 87 samples, 0.9 ml of the heat-
treated fecal suspension and 0.1 ml of the non-heated
suspension were mixed with 1 ml of Cary-Blair-medium.
Table 1 presents the procedure applied to standardize the
quantity of ESBL-producing bacteria inoculated on the
screening agars. Pure culture of each of the ESBL-
producing bacteria was suspended in 0.9% NaCl-solution.
The optical density (OD) was then adjusted to 0.40, mea-
sured with a spectrophotometer (Helios Epsilon from
Thermo Scientific). 30 μl of each pure-culture suspension
containing ESBL-producing isolates was added to the fecal
suspensions. In addition, to mimic normal growth, non-
ESBL E. coli (50–200 μl with an OD of 0.40) isolated from
the donor feces was added to the suspensions from a pure
culture. One droplet (50 μl, equivalent to ~8x104 CFU of
ESBL-positive culture) of each of the 87 spiked fecal sus-
pensions were spread onto each of the four ESBL screen-
ing agars, and on lactose-agar and XLD-agar as controls.
In addition, pure culture from the ESBL-carrying isolates
was inoculated onto the four screening agars to ensureTable 1 Content of the fecal suspension
Fecal suspension1
900 μL Heat treated feces (non-ESBL)
100 μL Non-heated feces (non-ESBL)
1000 μL Cary Blair-medium
30 μL Pure culture (ESBL) OD: 0.4 (1,2x108/mL)
50-200 μL Non-ESBL E. coli OD: 0.4 (1.2x108/mL)
~2100 μL
150 μL from this suspension was inoculated on each screening agar.that all the ESBL-carrying bacteria did grow on all four
media and to facilitate the reading of the corresponding
agars inoculated with the fecal specimens. All screening
agars were incubated in ambient air at 37°C. After 24 hours
incubation, the degree of growth was graded from 0; no
growth, to 3; excellent growth.
The preparation, inoculation and interpretation of the
culture media were manually performed.
ESBL screening media tested
Four commercially available selective media designed to
detect ESBL-producing bacteria directly from clinical
specimens were compared. ChromID ESBL (BioMèrieux,
Lyon, France), Brilliance ESBL (Oxoid, Basingstoke, United
Kingdom) BLSE agar (AES Laboratoire, Combourg, France)
and CHROMagar ESBL (CHROMagar, Paris, France) are
all selective agar media commercially available in Norway.
The BLSE agar is a bi-plate made of two different non-
chromogenic selective media, MacConkey agar and
Drigalski agar.
According to the product information provided by the
manufacturers, all four agars contain an extended-spectrum
cephalosporin, in combination with other antibacterial agents
to inhibit growth of non-ESBL Enterobacteriaceae. Both
ChromID ESBL and Brilliance ESBL media are supple-
mented with cefpodoxime in addition to an undeclared
mixture of antibacterial agents. The cefpodoxime con-
centration in these two plates is not given. The BLSE
MacConkey agar is supplemented with ceftazidime (2 mg/L)
while the BLSE Drigalski agar is supplemented with cef-
otaxime (1.5 mg/L). CHROMagar is supplemented with
an unknown mixture of antibacterial agents. Two of
the screening agars, Brilliance ESBL and CHROMagar
ESBL, are expected to suppress growth of AmpC-
producing bacteria while ChromID ESBL and BLSE agar
are designed to select also for AmpC-positive bacteria.
ChromID ESBL, Brilliance ESBL and CHROMagar con-
tain different chromogens which target different enzymes
within different bacterial species, resulting in coloured col-
onies making identification easier. The chromogenic sub-
strates differ between the three agars, but all of them seem
to target β-galactosidase and/or β-glucuronidase (Kleb-
siella, Serratia, Enterobacter and Citrobacter, commonly
known as the KSEC-group, and E. coli) and deaminase
(Proteus, Providencia and Morganella). According to the
manufacturers’ information, E. coli will appear pink on
ChromID and CHROMagar, and pink or blue on the
Brilliance agar. Furthermore, the KSEC-group will ap-
pear green on ChromID and Brilliance agar, while on
CHROMagar the KSEC-group will appear blue. Proteus,
Providencia and Morganella will appear brown on all three
chromogenic agars according to the product information.
It is known that Shigella sonnei produces β-galactosidase
and β-glucuronidase and will thus appear like E. coli on
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gella flexneri nor Salmonella generally produce any of
these enzymes and will consequently appear with
colourless colonies [29-31]. The appearance of Salmonella
and Shigella is, however, not stated by the manufacturers,
with the exception of the Brilliance ESBL agar. This
manufacturer describes that Salmonella will appear
colorless.
The BLSE agar does not contain a specific chromo-
genic substrate, but has the ability to detect and diffe-
rentiate ESBL-positive Enterobacteriaceae and other
multiresistant Gram negative bacilli based on their ability
to ferment lactose. The MacConkey agar and the
Drigalski agar both contain pH-indicators which diffe-
rentiates lactose-positive and lactose-negative bacteria
based on the color of the agar and the colonies. Most
species within the Salmonella and Shigella genera do not
have the ability to ferment lactose. However, Shigella
sonnei may ferment lactose, but only after extended
incubation [31].
ChromID ESBL, Brilliance ESBL and BLSE agar are
available as “ready to use” plates from the producers,
while CHROMagar ESBL is sold as a powder base.
Statistical analyses
The calculation of the sensitivity for detecting ESBL-
carrying isolates for each screening agar was based on a
total of 87 isolates, 51 isolates carrying ESBLA genotypes
and 36 carrying AmpC genotypes. The single isolate
which was both ESBLA - and AmpC positive was
counted as an AmpC in the statistical analysis. For each
agar plate the total sensitivity was calculated (ESBLA +
AmpC) (n = 87), as well as the sensitivity for ESBLA and
AmpC alone (n = 51 and n = 36, respectively). A 95%
confidence interval (95% CI) for each value was ma-
nually calculated using binomial proportions’ confidence
interval.
Results
The ESBL genotyping results are shown in Tables 2 and
3. The genotypic characterisation enabled prediction of
growth and color of the colonies growing on the various
media. The expected outcome was compared with the
observed results. The expected colony colours for Sal-
monella spp. and Shigella sonnei on each ESBL screeningTable 2 Distribution of ESBL-genes in the 87 isolates
ESBLA
CTX-M SHV-12 CTX-M −15 + SHV-12
Salmonella 26 3 4
Shigella 18 0 0
Total 44 3 4agar are shown in Figure 1. The grading of growth for
the 87 isolates is presented in Tables 4 and 5, respect-
ively. The calculated sensitivity is presented in Table 6.
ChromID ESBL
All of the 87 spiked fecal samples were expected to be
detected on ChromID ESBL agar as colourless colonies.
All of the 51 isolates carrying ESBLA genotypes, but only
32 of the 36 AmpC isolates were detected (Table 6). The
four AmpC isolates that did not grow on ChromID, all
carried blaCMY-2. Three Salmonella-isolates made pink
colonies while the rest of the growing Salmonella iso-
lates (n=62) produced colourless colonies. Shigella son-
nei (n=16) and Shigella flexneri isolates (n=2) produced
pink and colourless colonies, respectively. The total sen-
sitivity of ChromID ESBL was 95% (95% CI 90.4-99.6%),
the sensitivity for ESBLA was 100%, and the sensitivity
for AmpC was 89% (95% CI 78.8-99.2). ChromID ESBL
had overall higher graded growth with ESBLA-positive
strains than AmpC-positive (Tables 4 and 5).
Brilliance ESBL
The expected results for the Brilliance ESBL agar were
that all 51 isolates carrying ESBLA genotypes would
grow and appear as colourless colonies, in contrast to
the 36 AmpC isolates that should be suppressed. The
observed results showed that all the 51 ESBLA-positive
isolates were detected, while 30 of the 36 AmpC isolates
were not suppressed and did grow (Table 6). The growth
of these 30 AmpC-isolates was generally scored lower
than the ESBLA-isolates. Three Salmonella isolates pro-
duced pink colonies while the rest of the Salmonella iso-
lates (n=61) detected, produced colourless colonies.
Shigella sonnei (n=16) and Shigella flexneri (n=2) isolates
produced blue and colourless colonies, respectively. The
total sensitivity for ESBL detection of Brilliance ESBL
agar was 93% (9% CI 87.6-98.4%), the sensitivity for
ESBLA was 100% and the sensitivity for AmpC was 83%
(95% CI 70.7-95.3%).
BLSE agar
The expected results for CHROMagar ESBL were that
all 51 isolates with ESBLA genotypes would be detected
with colourless colonies, while the growth of the 36
AmpC isolates would be inhibited. The observed resultsESBLA + AmpC AmpC Total
TEM-63 + CMY-2 CMY-2 DHA-1
1 33 1 68
0 1 0 19
1 34 1 87




CTX-M 3/22 1 0
CTX-M-9 1 0
CTX-M 14/17/18 7 1
CTX-M 15 16 15
CTX-M-27 0 1
26 18
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isolates, but 23 of the 36 AmpC isolates were not inhib-
ited (Table 6). The growth of these 23 AmpC-isolates
was generally graded lower than the ESBLA-isolates. All
detected isolates of Salmonella (n=55) and ShigellaFigure 1 Picture of normal growth of Salmonella (left) and
Shigella sonnei (right) with ESBL genotypes. All ESBL positive
isolates were mixed with a fecal suspension controlled for the
absence of Salmonella, Shigella and any other ESBL-producing bacteria,
before being inoculated onto the screening agars. The Lactose and
XLD agars (top) were used as controls. a = Salmonella, b = Shigella
sonnei, 1 = Lactose + XLD (control agars), 2 = BLSE agar, 3 = Brilliance
ESBL, 4 = ChromID ESBL, 5 = CHROMagar ESBL.flexneri (n=17) produced colourless colonies while Shi-
gella sonnei (n = 2) produced pink colonies. The total
sensitivity for ESBL detection of CHROMagar was 85%
(95% CI 77.5-92.5%), the sensitivity for ESBLA detection
was 100% and the sensitivity for AmpC was 64% (95%
CI 48.3-79.7%).
CHROMagar ESBL
The expected results for CHROMagar ESBL were that
all 51 isolates with ESBLA genotypes would be detected
with colourless colonies, while the growth of the 36
AmpC isolates would be inhibited. The observed results
were that CHROMagar ESBL detected all the 51 ESBLA
isolates, but 23 of the 36 AmpC isolates were not inhib-
ited (Table 6). The growth of these 23 AmpC-isolates
was generally graded lower than the ESBLA-isolates. All
detected isolates of Salmonella (n = 55) and Shigella flex-
neri (n = 17) produced colourless colonies while Shigella
sonnei (n = 2) produced pink colonies. The total sensitivity
for ESBL detection of CHROMagar was 85% (95% CI
77.5-92.5%), the sensitivity for ESBLA detection was
100% and the sensitivity for AmpC was 64% (95% CI
48.3-79.7%).
Discussion
To the best of our knowledge, our study is the first com-
paring commercially available ESBL screening media, for
direct screening of ESBL-carrying Salmonella and Shigella
in fecal samples. One study conducted by Kocagöz et al.
[32] evaluated a novel chromogenic medium, Quicolor
E&S agar, for the detection of ESBL-producing Salmonella
spp. However, Quicolor E&S seems not to be designed for
the direct screening of clinical samples [32]. Since other
Enterobacteriaceae and non-Enterobacteriaceae carrying
ESBL have been evaluated in other studies, we did not
focus on these bacteria [33-36].
All bacterial isolates in the study had reduced sensitiv-
ity against cefpodoxime, and carried genotypes confer-
ring ESBLA or AmpC phenotypes; hence this study was
not designed to reveal false positive results. The specific-
ities of the four screening agars have been documented
in previous studies focusing on the ability to detect
ESBL-producing bacteria within the Enterobacteriaceae
family. These studies included none or just a few Salmon-
ella isolates, and the specificity varied greatly. ChromID
ESBL agar was included in most of the studies, and the
specificity ranged from 72.9% - 94.9% [33-36]. The specifi-
city of the Brilliance agar ranged from 57.9%– 95.1%
[33,34,36], and for BLSE agar the specificity ranged from
60.8-85.0% [34,35]. CHROMagar ESBL has been evaluated
by Grohs et al. only, with a reported specificity of 72.3%
[33]. However, some of the previous studies seem to
have included ESBL-producing non-Enterobacteriaceae
isolates as test positives, while other studies only included
Table 4 Grading of growth of 68 ESBLA- and/or AmpC-producing Salmonella isolates (n=68)
Growth Excellent Good Poor No growth
ESBLA AmpC ESBLA AmpC ESBLA AmpC ESBLA AmpC
Brilliance ESBL 31 9 1 5 1 17 4
BLSE agar* – Drigalski 31 35 1 1
BLSE agar* – Mac Conkey 31 34 1 1 1
CHROMagar ESBL 32 4 1 4 14 13
ChromID ESBL 33 12 16 4 3
All ESBL-producing isolates were mixed with a fecal suspension controlled for the absence of Salmonella, Shigella and any other ESBL-producing bacteria, before
being inoculated on the screening agars.
*BLSE agar is a biplate consisting of one half of Drigalski agar and one half of MacConkey agar.
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family. This difference may explain the apparent great
variations in specificities reported.
The frequency of human infection with Salmonella
and Shigella in Norway is relatively low. Consequently,
to gain proper statistical power in a real-life study evalu-
ating screening plates for ESBL-positive strains of these
two genera would be time consuming. We therefore
chose to use a suspension of a normal fecal sample
spiked with the ESBL- positive isolates. The quantity of
ESBL-positive bacteria in the fecal samples is known to
be a factor of the sensitivity of the screening agars [37].
In genuine fecal samples the quantity of bacteria varies,
but in this study we spiked the same quantity of bacteria
in all samples.
Salmonella are normally lactose negative and produce
neither β-galactosidase nor β-glucuronidase. Consequently,
colonies of Salmonella appeared colourless on agarplates
that use these enzymes in the chromogenic reactions. Shi-
gella sonnei is both β-glucuronidase and β-galactosidase-
positive and appeared much like E. coli on these screening
agars. Therefore direct differentiation of Shigella sonnei
and E. coli is difficult. However, none of the manufacturers
mention this similarity in their product information. On
the other hand, Shigella flexneri does not express these en-
zymes, and will not appear like E. coli on the screeningTable 5 Grading of growth, of 19 ESBLA- or AmpC-producing
Growth Excellent G
ESBLA AmpC ESBLA
Brilliance ESBL agar 18
BLSE agar* – Drigalski 16 1 2
BLSE agar* – Mac Conkey 15 1 3
CHROMagar ESBL 18
ChromID ESBL 17 1
All ESBL-producing isolates were mixed with a fecal suspension controlled for the a
being inoculated on the screening agars.
*BLSE agar is a biplate consisting of one half of Drigalski agar and one half of MacCagars. This was confirmed in our testing. Obviously, testing
only two Shigella flexneri isolates is insufficient to give a
statistically reliable result. Three Salmonella isolates of dif-
ferent serovars had pink colonies on both ChromID and
Brilliance agars, whereas the rest of the Salmonella isolates
had colorless colonies. It is necessary for the pink color
formation that the bacteria express β-glucuronidase, which
is described that some Salmonella bacteria actually do [38].
The color-based identification was non-specific and com-
parable to expected results from using a non-chromogenic
agar with the same antibacterial supplements. Conse-
quently, any growth on the ESBL screening agars, re-
gardless of manufacturer, needs to be further confirmed
by phenotypic or genotypic analyses. The BLSE agar
which distinguishes the bacterial species according to
their lactose fermentation capability separates E. coli
and Klebsiella from Salmonella and Shigella. The man-
ufacturers of Brilliance agar and CHROMagar claim
that their screening agars inhibit the growth of AmpC-
positive bacteria. This may limit the use of these growth
media since plasmid-mediated AmpC is increasing in
prevalence. On the other hand, specific ESBLA detec-
tion can be useful in the clinical setting of outbreak with
ESBLA carrying strains. In our study, both Brilliance
agar and CHROMagar did not inhibit growth of AmpC-
positive strains in the way that the producers claim theyShigella isolates (n=19)
ood Poor No growth




bsence of Salmonella, Shigella and any other ESBL-producing bacteria, before
onkey agar.
Table 6 A comparison of the expected and observed result, colour of colonies and sensitivity





Observed /Expected ESBLA-positive 51/51 51/51 50/51 50/51 51/51
Observed/Expected AmpC-positive 32/36 31/0 36/36 36/36 23/0
Expected colour of colonies Colourless Colourless Blue White Colourless
Colour of Salmonella colonies Colourless (n = 62)
Pink (n = 3)
Colourless (n = 61)
Pink (n = 3)
Blue Pale pink Colourless
Colour of Shigella sonnei colonies Pink Blue Blue Pale pink Pink
Colour of Shigella flexneri colonies Colourless Colourless Blue Pale pink Colourless
Sensitivity (95% CI*) 95% (90.4 - 99.6) 93% (87.6 - 98.4) 99% (96.9 - 100) 99% (96.9 - 100) 85% (77.5 - 92.5)
Sensitivity ESBLA (95% CI*) 100% 100% 98% (94.2 - 100) 98% (94.2 - 100) 100%
Sensitivity AmpC (95% CI*) 89% (78.8 - 99.2) 83% (70.7 - 95.3) 100% 100% 64% (48.3 - 79.7)
A total of 87 ESBL-producing isolates (51 = ESBLA, 36 = AmpC) were inoculated on the four screening agars. BLSE agar is a biplate consisting of two different agars;
Drigalski agar and MacConkey agar. The isolates were mixed with a fecal suspension before inoculation. The expected results are estimated by the manufacturer’s
product information.
*CI = 95% Confidence interval.
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lates included in this study belonged to the CMY-2
genotype and this result may not be generalizable to
other genotypes. Our results also showed that these
media did not support growth of AmpC-positive isolates
as well as they did for ESBLA-positive isolates indicating
that the growth was suppressed rather than totally inhib-
ited. This observation may be of importance in real fecal
samples where mixed bacterial flora may lead to overgrow
of partly suppressed slow growing AmpC-positive isolates.
However, in this study when interpreting the growth on
the agars, any growth was considered positive.
There was no pronounced difference between different
serovars in the material. The isolates which were inhib-
ited consisted of nine different Salmonella serovars and
one Shigella sonnei. Other isolates belonging to the same
serovars as the inhibited isolates showed excellent growth
on all agars, except S. Cholerasuis which were inhibited
on CHROMagar, ChromID and Brilliance agar. There was
only one S. Cholerasuis included in this study and no
conclusion can be made from this isolate alone.
We find that the sensitivity for ESBL detection of
ChromID agar and BLSE agar was satisfying, and that both
agars enabled the detection of almost every ESBL-positive
isolate, regardless of ESBL genotype or serovar/serogroup.
The Drigalski part of the BLSE agar was the only agar that
showed both Salmonella and Shigella isolates with colored
colonies. The blue color indicated that the bacteria
were lactose-negative or that the lactose fermentation
was dependent of an extended incubation. The blue
colour enabled differentiation of Salmonella and Shigella
from the most usual ESBL-producing E. coli and Klebsiella
spp. The blue colour does not differentiate the isolate from
multi resistant Gram negative bacilli other than Entero-
bacteriaceae, such as Pseudomonas aeruginosa, Acineto-
bacter and Stenotrophomonas maltophilia.Conclusions
The main conclusion of this study is that the method of
screening fecal samples by the use of selective agar
plates was easy to perform and the four agars detected
the presence of ESBL-carrying bacteria in overnight cul-
tures. All four agar media appeared reliable for screening
for both Salmonella and Shigella with ESBLA genotypes
from fecal samples. However, only ChromID agar and
BLSE agar were reliable in detecting isolates with AmpC.
Furthermore, the BLSE agar had the highest sensitivity
and was the only agar which differentiated E. coli and
Klebsiella from Salmonella and Shigella by the colour of
the colonies. The three other agars differentiated E. coli
and Klebsiella from Salmonella and Shigella flexneri by
the colourless colonies of Salmonella and Shigella flex-
neri and the coloured colonies of E. coli and Klebsiella.
These three agars did not enable differentiation between
E. coli and Shigella sonnei. The BLSE agar and the Chro-
mID were both good alternatives for screening of fecal
specimens with ESBL positive Salmonella or Shigella.
The BLSE agar had the highest sensitivity, while Chro-
mID had fairly good sensitivity. ChromID had a higher
sensitivity for ESBLA-than AmpC bacteria, while BLSE
agar was equally sensitive to both ESBLA- and AmpC
bacteria. Because detection of ESBL-carrying Salmonella
and Shigella is highly important both in clinical settings
and for surveillance purposes, the strengths and weak-
nesses hereby reported should be taken into consideration
when using any of these four commercially ESBL screen-
ing agars.Authors’ contributions
KS contributed to the design, laboratory experiments, analysed data and
drafted the manuscript. URD, MS and ALW contributed to conception and
design, data analysis and the writing of the manuscript. ESB contributed to
design, establish methods, data analysis, and writing of the manuscript. All
authors read and approved the final manuscript.
Sturød et al. BMC Microbiology 2014, 14:217 Page 8 of 9
http://www.biomedcentral.com/1471-2180/14/217Competing interests and ethical concerns
The authors have no competing interests. Because the bacterial isolates
included in the study had no patient information attached, ethical approval
was unnecessary. The fecal specimen used, was given by one of the
technicians, with this person’s consent.
Acknowledgements
We thank Kristina Olsson and Julie Øvstegård for the practical work in
association with their bachelor assignment. We thank Torbjørn Bruvik and
Inger Løbersli for assistance with the ESBL genotyping. We also thank The
Reference Center for Detection of Antimicrobial resistance (K-res), University
Hospital of North Norway, for their contribution with training of staff, for the
sharing of protocols and for providing control strains.
Funding
This work was financially supported by the Reference Committee on the
Norwegian quality assurance system for bacteriology, mycology and
parasitology.
Author details
1Department of Food-borne Infections, Oslo, Norway. 2Department of
Bacteriology and Immunology, Division of Infectious Disease Control,
Norwegian Institute of Public Health, Postbox 4404Nydalen, 0403 Oslo,
Norway.
Received: 1 April 2014 Accepted: 12 August 2014
Published: 4 September 2014
References
1. Antimicrobial resistance. http://www.who.int/mediacentre/factsheets/
fs194/en/index.html.
2. Pfaller MA, Segreti J: Overview of the epidemiological profile and
laboratory detection of extended-spectrum beta-lactamases. Clin Infect
Dis 2006, 42(Suppl 4):S153–S163.
3. NORM/NORM-VET 2012: Usage of antimicrobial agents and occurrence of
antimicrobia resistance in Norway. Tromsø/Oslo: 2013. ISBN 1502-2307
(print)/1890-9965 (electronic).
4. ECDC (European Centre for Disease Prevention and Control): Antimicrobial
resistance surveillance in Europe 2012. In Annual Report of the European
Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: 2013.
5. de Kraker ME, Davey PG, Grundmann H: Mortality and hospital stay
associated with resistant Staphylococcus aureus and Escherichia coli
bacteremia: estimating the burden of antibiotic resistance in Europe.
PLoS Med 2011, 8(10):e1001104.
6. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, Voets GM, van den
Munckhof MP, van Essen-Zandbergen A, Platteel T, Fluit AC, van de
Sande-Bruinsma N, Scharinga J, Bonten MJ, Mevius DJ: Dutch patients,
retail chicken meat and poultry share the same ESBL genes, plasmids
and strains. Clin Microbiol Infect 2011, 17(6):873–880.
7. Kluytmans JA, Overdevest IT, Willemsen I, den Bergh MF K-v, van der
Zwaluw K, Heck M, Rijnsburger M, Vandenbroucke-Grauls CM, Savelkoul PH,
Johnston BD, Gordon D, Johnson JR: Extended-spectrum
beta-lactamase-producing Escherichia coli from retail chicken meat and
humans: comparison of strains, plasmids, resistance genes, and virulence
factors. Clin Infect Dis 2013, 56(4):478–487.
8. Woerther PL, Burdet C, Chachaty E, Andremont A: Trends in human fecal
carriage of extended-spectrum beta-lactamases in the community:
toward the globalization of CTX-M. Clin Microbiol Rev 2013, 26(4):744–758.
9. Carattoli A: Animal reservoirs for extended spectrum beta-lactamase
producers. Clin Microbiol Infect 2008, 14(Suppl 1):117–123.
10. Seiffert SN, Hilty M, Perreten V, Endimiani A: Extended-spectrum
cephalosporin-resistant Gram-negative organisms in livestock: an emerging
problem for human health? Drug Resist Updat 2013, 16(1–2):22–45.
11. Carattoli A: Resistance plasmid families in Enterobacteriaceae. Antimicrob
Agents Chemother 2009, 53(6):2227–2238.
12. Carattoli A: Plasmids and the spread of resistance. Int J Med Microbiol
2013, 303(6–7):298–304.
13. Ostholm-Balkhed A, Tarnberg M, Nilsson M, Nilsson LE, Hanberger H,
Hallgren A: Travel-associated faecal colonization with ESBL-producing
Enterobacteriaceae: incidence and risk factors. J Antimicrob Chemother
2013, 68(9):2144–2153.14. Soraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA: Risk factors for
community-acquired urinary tract infections caused by ESBL-producing
enterobacteriaceae–a case–control study in a low prevalence country.
PLoS One 2013, 8(7):e69581.
15. Tangden T, Cars O, Melhus A, Lowdin E: Foreign travel is a major risk
factor for colonization with Escherichia coli producing CTX-M-type
extended-spectrum beta-lactamases: a prospective study with Swedish
volunteers. Antimicrob Agents Chemother 2010, 54(9):3564–3568.
16. Jertborn M, Haglind P, Iwarson S, Svennerholm AM: Estimation of
symptomatic and asymptomatic Salmonella infections. Scand J Infect Dis
1990, 22(4):451–455.
17. Gaudio PA, Sethabutr O, Echeverria P, Hoge CW: Utility of a
polymerase chain reaction diagnostic system in a study of the
epidemiology of shigellosis among dysentery patients, family
contacts, and well controls living in a shigellosis-endemic area.
J Infect Dis 1997, 176(4):1013–1018.
18. Jacoby GA: AmpC beta-lactamases. Clinical Microbiol Rev 2009,
22(1):161–182. Table of Contents.
19. Philippon A, Arlet G, Jacoby GA: Plasmid-determined AmpC-type beta-lactamases.
Antimicrob Agents Chemother 2002, 46(1):1–11.
20. Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J: Comparison of
nine phenotypic methods for detection of extended-spectrum
beta-lactamase production by Enterobacteriaceae. J Clin Microbiol
2011, 49(3):1048–1057.
21. Willems E, Verhaegen J, Magerman K, Nys S, Cartuyvels R: Towards a
phenotypic screening strategy for emerging β-lactamases in Gram-negative
bacilli. Int J Antimicrob Agents 2013, 41(2):99–109.
22. Overvåkning av problembakterier i sykehus. In Norwegian Institute of
Public Health; 2012. http://www.fhi.no/dokumenter/0f6b78a4e2.pdf
(3. Mars 2014, date last accessed).
23. Forebygging og kontroll av spredning av multiresistente gramnegative
stavbakterier og ESBL-holdige bakterier i helseinstitusjoner. In Norwegian
Institute of Public Health; 2009. http://www.fhi.no/dokumenter/96331178b9.
pdf (4. Mars 2014, date last accessed).
24. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR,
Sundsfjord A: Effects of phenotype and genotype on methods for
detection of extended-spectrum-beta-lactamase-producing clinical
isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
J Clin Microbiol 2007, 45(1):199–205.
25. Monis PT, Giglio S, Saint CP: Comparison of SYTO9 and SYBR Green I for
real-time polymerase chain reaction and investigation of the effect of
dye concentration on amplification and DNA melting curve analysis.
Anal Biochem 2005, 340(1):24–34.
26. Berg ES NT: High resolution Melt Analysis. In PCR Technology: Current
Innovations. 3rd edition. Edited by Nolan TBS. Boca Raton FL: CRC Press,
Taylor & Francis Group; 2013:409–421.
27. Brolund A, Wisell KT, Edquist PJ, Elfstrom L, Walder M, Giske CG:
Development of a real-time SYBRGreen PCR assay for rapid detection of
acquired AmpC in Enterobacteriaceae. J Microbiol Methods 2010,
82(3):229–233.
28. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and
analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999,
41:95–98.
29. Lampel KA, Sandlin R: SHIGELLA. In Encyclopedia of Food Sciences and
Nutrition (Second Edition). Edited by Caballero B. Oxford: Academic Press;
2003:5261–5268.
30. Cleuziat P, Robert-Baudouy J: Specific detection of Escherichia coli and
Shigella species using fragments of genes coding for β-glucuronidase.
FEMS Microbiol Lett 1990, 72(3):315–322.
31. Nataro JP Bopp CA, Fields PI, Kaper JB, Strockbine NA: Escherichia, Shigella
and Salmonella. In Manual of Clinical Microbiology, Volume 1. 10th edition.
Edited by Versalovic V. Washington DC: ASM Press; 2011.
32. Kocagoz S, Budak F, Gur D: Evaluation of a chromogenic medium for
rapid detection of extended spectrum beta-lactamase producing
Salmonella spp. Indian J Med Res 2006, 124(4):443–446.
33. Grohs P, Tillecovidin B, Caumont-Prim A, Carbonnelle E, Day N, Podglajen I,
Gutmann L: Comparison of five media for detection of extended-spectrum
Beta-lactamase by use of the wasp instrument for automated specimen
processing. J Clin Microbiol 2013, 51(8):2713–2716.
34. Willems E, Cartuyvels R, Magerman K, Verhaegen J: Evaluation of 3 different
agar media for rapid detection of extended-spectrum β-lactamase–producing
Sturød et al. BMC Microbiology 2014, 14:217 Page 9 of 9
http://www.biomedcentral.com/1471-2180/14/217Enterobacteriaceae from surveillance samples. Diagn Microbiol Infect Dis 2013,
76(1):16–19.
35. Reglier-Poupet H, Naas T, Carrer A, Cady A, Adam JM, Fortineau N, Poyart C,
Nordmann P: Performance of chromID ESBL, a chromogenic medium for
detection of Enterobacteriaceae producing extended-spectrum
beta-lactamases. J Med Microbiol 2008, 57(Pt 3):310–315.
36. Huang TD, Bogaerts P, Berhin C, Guisset A, Glupczynski Y: Evaluation of
Brilliance ESBL agar, a novel chromogenic medium for detection of
extended-spectrum-beta- lactamase-producing Enterobacteriaceae.
J Clin Microbiol 2010, 48(6):2091–2096.
37. Sturenburg E, Sobottka I, Laufs R, Mack D: Evaluation of a new screen agar
plate for detection and presumptive identification of Enterobacteriaceae
producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis
2005, 51(1):51–55.
38. Le Minor L, Buissiere J, Novel G, Novel M: Correlation between
beta-glucuronidase activity and serotype in the genus “Salmonella”
(author’s transl). Ann Microbiol (Paris) 1978, 129b(2):155–165.
doi:10.1186/s12866-014-0217-3
Cite this article as: Sturød et al.: Evaluation of the ability of four EBSL-
screening media to detect ESBL-producing Salmonella and Shigella. BMC
Microbiology 2014 14:217.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
